CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTechAccesswire • 07/11/24
Agomab Bolsters Executive Team with Appointment of Pierre Kemula as Chief Financial OfficerBusiness Wire • 07/11/24
CureVac's stock soars on GSK's $1.56 billion deal for its COVID-19 and flu vaccinesMarket Watch • 07/03/24
CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline OpportunitiesAccesswire • 07/03/24
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business UpdateAccesswire • 04/24/24
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSKAccesswire • 04/24/24
CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024Accesswire • 04/18/24
CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer VaccinesAccesswire • 04/16/24
CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSKAccesswire • 04/04/24
Down -14.25% in 4 Weeks, Here's Why You Should You Buy the Dip in CureVac N.V. (CVAC)Zacks Investment Research • 01/26/24
Down -15.09% in 4 Weeks, Here's Why You Should You Buy the Dip in CureVac N.V. (CVAC)Zacks Investment Research • 01/25/24
CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology PlatformAccesswire • 01/05/24
CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SEAccesswire • 12/19/23
Can CureVac N.V. (CVAC) Climb 191.74% to Reach the Level Wall Street Analysts Expect?Zacks Investment Research • 11/21/23